• Title/Summary/Keyword: 백신 접종

Search Result 462, Processing Time 0.025 seconds

Immune response of olive flounder, Paralichthys oliveceus against B-hemolytic Streptococcus ineae formalin-killed cells (B-용혈성 Streptococcus ineae 포르말린 사균 백신에 대한 넙치의 면역 반응)

  • Jo, Mi-Young;Lee, Deok-Chan;Kim, Jin-Woo;Lee, Ju-Seok;Choi, Hee-Jung
    • Journal of fish pathology
    • /
    • v.19 no.1
    • /
    • pp.73-82
    • /
    • 2006
  • Streptococcal infections were considered as a serious problem because of significant economic losses in fish farm industry. We evaluated the efficacies of Streptococcus iniae vaccines in olive flounder, Paralichthys olivaceus. The vaccines were prepared from 10% neutral buffered formalin to give a final concentration of 0.3% or 3%, respectively. Fish were immunized by intraperitoneal injection of the experimental vaccines once or twice. Neither of the vaccines gave rise to any significant side effects. The antibody titers of booster immunized groups were significantly higher than those of prime immunized groups with both of the vaccines. According to formalin dosage, significantly increased antibody titers were produced by 3% formalin-killed cells (FKC) at 4weeks and 8weeks after prime and booster vaccination, respectively. Although the different levels of antibody production were showed by the vaccinated fish, the good protection obtained in challenge trials of the both vaccines. Fish immunized with 0.3% FKC once or twice had the relative percent survival (RPS) of 66.7% and 87.5%, respectively. Similarly, fish immunized with 3% FKC once or twice had the RPS of 70.0% and 77.0%, respectively. Further experiments are needed to study not only correlation between the antibody titers and RPS against S. iniae but also the side effects of high dose of formalin on antigenicity.

Adverse Events Associated with MMR Vaccination in Korea - Prospective Study Using Telephone Surveillance Method - (MMR 백신 부작용 발생 실태 - 보건소 전화 조사를 통한 전향적 연구 -)

  • Lee, Jin Soo;Ki, Mo Ran;Sohn, Young Mo
    • Pediatric Infection and Vaccine
    • /
    • v.7 no.2
    • /
    • pp.183-192
    • /
    • 2000
  • Purpose : Adverse events(AE) associated with vaccination have not been systematically monitored in Korea. But since 1994, several deaths after inactivated mouse brain derived Japanese encephalitis vaccine injection arouse the safety problem of immunization in the public, and a evaluation of vaccination program including the effectiveness and safety problem had been started. We have been using MMR vaccine containing Japanese mumps vaccine strains, which are known to be associated with the high rate of adverse events including aseptic meningitis, for the last decade. Methods : We conducted a prospective study of vaccine adverse events associated with MMR vaccine through a tracking system using telephone calls. We followed up 7,594 cases of MMR vaccinees. Results : Reported adverse events included fever, couvulsion, parotitis, and aseptic meningitis. Nine cases of parotitis and seven cases of aseptic meningitis were recognized during follow up period. The incidence of both parotitis and aeptic meningitis was $85.1/10^5$, for Urabe mumps strain. For Hoshino strain, the incidence of parotitis and aseptic meningitis was $158.0/10^5$ and $94.8/10^5$, respectively. Conclusions : The incidence of adverse events was to be a higher than that of natural infection in Korea and was comparable to the results of studies done in other countries.

  • PDF

Descriptive analysis of COVID-19 statistics across nations (OECD 국가별 코로나19의 기술 통계 분석)

  • Ji-sun An;Mingue Park
    • The Korean Journal of Applied Statistics
    • /
    • v.36 no.5
    • /
    • pp.447-455
    • /
    • 2023
  • COVID-19 is an emerging infectious disease that is hard to predict in terms of fatality rate, treatments, and the timing of its end. World is developing treatments and vaccines for COVID-19. Several treatments and vaccines currently have emergency use authorization, but the treatments are only allowed for critically ill patients with COVID-19. Therefore, the aim of this study is to analyze the confirmed cases of COVID-19, including mortality and testing, in OECD countries and to assess the effect of vaccination on mortality. Looking at the confirmed cases, mortality, and vaccination rates of COVID-19, the number of confirmed cases was lower than previously reported cases after full vaccination. In early 2022, with Omicron, the confirmed cases increased sharply, while mortality dropped, and the mortality showed a gentle curve as the cumulative fully vaccinated exceeded 50%. This indicates that COVID-19 vaccines have an effect on reducing mortality. However, the duration of effectiveness of vaccines was considerably short, which decreased the initial inoculation effect and increased the monthly mortality. As this study was carried out during the COVID-19 pandemic, there was not enough data to analyze comprehensively. However, it is meaningful to compare and analyze the impact of COVID-19 by country.

Discussion of COVID-19 Vaccination and Axillary Lymph Nodes Uptake in 18F-FDG PET/CT (18F-FDG PET/CT에서 코로나 백신접종과 액와 림프절 섭취에 대한 고찰)

  • Min-Chan, Kim;Yong-Hoon, Choi;Han-Sang, Lim;Jae-Sam, Kim
    • The Korean Journal of Nuclear Medicine Technology
    • /
    • v.26 no.2
    • /
    • pp.32-36
    • /
    • 2022
  • Purpose There are reports that the COVID-19 vaccine causes false positive uptake of axillary lymph nodes. Therefore, this paper intends to evaluate the change in SUVmax of axillary lymph nodes with the period after the COVID-19 vaccination. Materials and Methods In 134 breast cancer patients who were tested for 18F-FDG PET/CT at Severance hospital, 3.7 MBq/kg of 18F-FDG was intravenously injected and scanned for 2 minutes per bed after 60 minutes. The equipment was Discovery 600 (GE Healthcare, MI, USA). The period was divided into four groups, 0 to 2 weeks, 3 to 6 weeks, 7 to 10 weeks, and 11 weeks or more. SUVmax was measured after checking the uptake of axillary lymph nodes on the ipsilateral side of vaccination and the Kruskal-Wallis test was performed using SPSS Statistics 28 (IBM Corp., Armonk, NY, USA). Results From 0 to 2 weeks groups to 11 weeks or more group, the average of SUVmax was measured in the order of 5.52, 2.85, 1.82, and 1.7. As a result of the Kruskal-Wallis test, there was a significant difference between 0 to 2 weeks group from all other groups (P < 0.05), and there was no significant difference between the remaining three groups. Conclusion The SUVmax of axillary lymph nodes decreased over the period after the COVID-19 vaccination and no significant difference was found after 3 weeks of vaccination. Therefore, it is recommended to record COVID-19 vaccination information before examination.

특정병원체 부재종란(Specific Pathogen Free Egg) 생산 및 관리요령

  • 대한양계협회
    • KOREAN POULTRY JOURNAL
    • /
    • v.13 no.7 s.141
    • /
    • pp.29-31
    • /
    • 1981
  • 난계대 질병을 막아야 한다는 생각은 오래 전부터 갖고 있었으나 그간 여건이 허락치 않아서 양축가들은 막대한 피해를 입으면서도 어쩔 수 없이 당하고만 있었다. 생독 백신을 접종하고 나면 닭에서 C.R.D.증세가 나타나는 등 부작용이 나타나서 백신접종을 기피하고나 또는 종계에서는 생독을 피하고 사독을 사용하는 경우도 있었다. 그러나 이제 양계 규모가 대형화함에 따라 일일히 사독을 주사할 수도 없고 어쩔 수 없이 음수용 생독을 사용치 않을 수 없는 형편에 이르고 있다. 다행히 정부는 그간 양축가의 건의를 받아들여 이번에 S.P.F.(특정 병원체 부재종란) 생산 및 관리요령을 고시함으로써 국내에서도 정식으로 S.P.F.종란의 생산 및 관리를 정부의 지도 감독하에 행하게 되어 믿고 쓸수 있게 되었다. 앞으로 백신 제조회사는 생독 백신을 모두 이 S.P.F.종란으로 만들겠지만 그간 S.P.F.종란을 수입해서 만든 백신이 가격 때문에 양축가로부터 외면당했던 점을 생각해서 앞으로는 양축가들이 즐겨 사용하도록 가능한 한 싼 값으로 제조$\cdot$판매되어야 할 것이고, 양축가는 우선 백신값은 약간 비싸지더라도 백신을 통한 난계대 질병으로부터의 해방으로 더 큰 이익을 가져 올 수 있다는 점을 생각해야 될 것이다. 이 땅에서 난계대 전염병을 완전 축출할 때까지는 생산자와 백신회사, 정부는 물론 모든 관련업계의 공동 방역 노력이 필요하겠다.

  • PDF

Vaccination Studies against Fowl Pox in Chickens (닭에서 계두 예방 접종에 관한 연구)

  • Shil, N.K.;Rahman, M.S.;Paul, S.;Cha, S.Y.;Jang, H.K.;Song, H.J.
    • Korean Journal of Poultry Science
    • /
    • v.34 no.4
    • /
    • pp.253-257
    • /
    • 2007
  • Fayoumi chicks were vaccinated with fowl pox virus vaccine and pigeon pox virus vaccine. The protective potentiality of the two vaccines was compared in field condition in Bangladesh. The percentage of 'take reaction' was assessed to conclude its relationship with better immune response and recorded 93.33% and 100% in birds of group B and group C, respectively. The mean passive hemagglutination (PHA) antibody titre after primary vaccination was $32{\pm}14.81$ in group B and $33{\pm}13.66$ in group C. Following booster vaccination, the mean PHA titres level at pre challenge of group B was $46.93{\pm}16.52\;and\;55.46{\pm}14.64$ in group C. The PHA titre of group B and C at two weeks post challenge recorded $93.86{\pm}33.04\;and\;110.93{\pm}29.29$, respectively. PHA titre significantly (P<0.01) increased after vaccination and post challenge compared to pre- vaccination titre. There was significant variation (p<0.01) of PHA titre at pre challenge in these groups using different vaccine combinations, but all the vaccinated birds resisted challenge infection.

Immunogenicity, Reactogenicity and Safety of a Combined DTPa-IPV Vaccine Compared with Separate DTPa and IPV Vaccines in Healthy Korean Infants (한국의 건강한 영아를 대상으로 DTPa-IPV 혼합백신을 접종한 경우와 DTPa 백신과 IPV 백신을 각각 투여하였을 경우의 면역원성, 반응원성 및 안전성)

  • Kim, Chang Hwi;Cha, Sung Ho;Shin, Son Moon;Kim, Chun Soo;Choi, Young Youn;Hong, Young Jin;Chey, Myoung Jae;Kim, Kwang Nam;Hur, Jae Kyun;Jo, Dae Sun;Kim, Sung Shin;Lee, Sang Lak;Song, Eun Song;Ramakrishnan, Gunasekaran;Ok, Jin Ju;Van Der Meeren, Olivier;Bock, Hans L.;Kim, Jung Soo
    • Pediatric Infection and Vaccine
    • /
    • v.17 no.2
    • /
    • pp.156-168
    • /
    • 2010
  • Purpose : To compare immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine (DTPa-IPV, $Infanrix^{TM}$ IPV, GlaxoSmithKline Biologicals) with co-administration of commercially available DTPa and IPV vaccines at separate injection sites (DTPa+IPV). Methods : A total of 458 infants aged 8-12 weeks were randomized to receive three-ose primary vaccination at 2, 4 and 6 months with DTPa-IPV or DTPa+IPV. Blood samples were collected pre and post vaccination for measurement of immune responses. Reactogenicity was assessed following each dose using diary cards. Results : One month post-dose 3, seroprotection rates for anti-diphtheria, anti-tetanus and anti-poliovirus types 1, 2 and 3 were ${\geq}99.5%$ and vaccine response rates to pertussis antigens were at least 98.6% in both DTPa-IPV and DTPa + IPV groups. Non-inferiority between the groups was demonstrated based on pre-defined statistical criteria. Incidences of both local and systemic symptoms were within the same range across both groups with grade 3 symptoms reported following no more than 4.3% of DTPa-IPV doses and 4.5% of DTPa + IPV doses. Two serious adverse events (both pyrexia) after DTPa-IPV administration were considered vaccine-related. Both infants recovered fully. Conclusion : Combined DTPa-IPV vaccine was immunogenic and well tolerated when used as a three-dose primary vaccination course in Korean infants. DTPa-IPV could be incorporated into the Korean vaccination schedule, reducing the number of injections required to complete primary immunization.

Occurrence Pattern of Intussusception according to the Introduction of Rotavirus Vaccine: An Observational Study at a University Hospital (로타바이러스 백신 도입에 따른 장겹침증 발생 경향: 한 대학병원 관찰 연구)

  • Nam, Hye Na;Lim, Kyung In;Tchah, Hann;Ryoo, Eell;Sun, Yong Han;Cho, Hye-Kyung
    • Pediatric Infection and Vaccine
    • /
    • v.23 no.3
    • /
    • pp.202-208
    • /
    • 2016
  • Purpose: Rotavirus vaccine (RV) was introduced in Korea since 2007, and intussusception (IS) remains an important safety concern. This study investigated the trend of IS occurrence related to RV as well as the temporal relevance between vaccination and IS in children. Methods: We collected data of the patient aged ${\leq}18$ years with IS admitted to Gachon University Gil Medical Center, 2003 to 2015. For the patients that have occurred since 2008, the immunization records of RV were collected. The proportion of cases <1 year was calculated by the year and the temporal relationship between vaccination and IS occurrence was analyzed. Results: A total of 696 IS cases were noted. The cases <1 year were 30.7% (214/696). Although the incidence of all IS has increased over the 13-year period (from 74.1 in 2003 to 89.5 in 2015, linear by linear association, P=0.003), the incidence of IS <1 year has not increased (from 56.9 in 2003 to 53.3 in 2015, P=0.910), and the proportion of cases <1 year has decreased (from 35.4 in 2003 to 18.8 in 2015, P=0.000). Of 128 cases <1 year since 2008, 53.9% received RV. In the vaccinated group, 10 cases of IS occurred within 30 days, and eight cases did within 31 to 60 days. Numbers of IS after first, second, and third dose were three, 10, and five cases, respectively. Conclusions: Occurrence of IS in children <1 year of age did not increase since the introduction of RV. Further monitoring is essential for evaluation of vaccine safety.

Comparison of Split versus Subunit Seasonal Influenza Vaccine in Korean Children over 3 to under 18 Years of Age

  • Kang, Seah;Kim, Dong Ho;Eun, Byung Wook;Kim, Nam Hee;Kang, Eun Kyeong;Lee, Byong Sop;Kim, Yun-Kyung
    • Pediatric Infection and Vaccine
    • /
    • v.26 no.3
    • /
    • pp.161-169
    • /
    • 2019
  • Purpose: This study was conducted to compare immunogenicities and reactogenicities of the trivalent inactivated subunit influenza vaccine and split influenza vaccine in Korean children and adolescents. Methods: In total, 202 healthy children aged 36 months to <18 years were enrolled at six hospitals in Korea from October to December 2008. The subjects were vaccinated with either the split or subunit influenza vaccine. The hemagglutinin inhibition antibody titers against the H1N1, H3N2, and B virus strains were measured, and the seroconversion rates, seroprotection rates, and geometric mean titers were calculated. All subjects were observed for local and systemic reactions. Results: Both the split and subunit vaccine groups had similar seroprotection rates against all strains (95.9%, 94.9%, 96.9% vs. 96.0%, 90.9%, and 87.9%). In children aged 36 to <72 months, the seroprotection rates were similar between the two vaccine groups. In children aged 72 months to <18 years, both vaccines showed high seroprotection rates against the H1N1, H3N2, and B strain (98.4%, 98.4%, 98.4% vs. 97.0%, 95.5%, and 91.0%), but showed relatively low seroconversion rates (39.1%, 73.4%, 35.9% vs. 34.3%, 55.2%, and 38.8%). There were more local and systemic reactions in the split vaccine group than in the subunit vaccine group; however, no serious adverse reactions were observed in both groups. Conclusions: Both the split and subunit vaccines showed acceptable immunogenicity in all age groups. There were no serious adverse events with both vaccines.